← Human Trials & Peer-Reviewed Studies
Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism
Plain-language guide to PMID 21595854 (2011): clinical trial study of Parathyroid Hormone (PTH 1-84) in 53 patients, hyperparathyroidism.
Key Facts
- PMID
- 21595854
- Journal
- Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
- Year
- 2011
- Study type
- Clinical Trial
- Authors
- Tanaka H et al. (5 authors)
- DOI
- 10.1111/j.1744-9987.2011.00928.x
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism.
A novel, electrochemiluminescence immunoassay that exclusively measures full-length parathyroid hormone (PTH), called Elecsys PTH (1-84) assay, is currently under development for clinical use.
The researchers measured serum PTH levels using this novel assay, as well as the Elecsys Intact PTH assay and the Whole PTH immunoradiometric assay, in 53 hemodialysis patients who participated in a 52-week clinical trial of cinacalcet.
Who Took Part
The abstract describes 53 patients taking part.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
How the Study Was Run
A time span of 52 weeks appears in the methods.
What Was Measured
A novel, electrochemiluminescence immunoassay that exclusively measures full-length parathyroid hormone (PTH), called Elecsys PTH (1-84) assay, is currently under development for clinical use.
The researchers measured serum PTH levels using this novel assay, as well as the Elecsys Intact PTH assay and the Whole PTH immunoradiometric assay, in 53 hemodialysis patients who participated in a 52-week clinical trial of cinacalcet.
The subject headings attached to it are Cinacalcet, Electrochemistry, Hyperparathyroidism, Secondary, Immunoassay, Immunoradiometric Assay, Kidney Diseases and Luminescent Measurements.
What This Means in Plain Language
This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 53 patients in people with hyperparathyroidism over 52 weeks.
The publication is from 2011 (Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy), a journal based in Australia.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.